Cargando…

COVID-19 pandemic and trends in new diagnosis of atrial fibrillation: A nationwide analysis of claims data

BACKGROUND: Atrial fibrillation (AF) is associated with a five-fold increased risk of stroke and a two-fold increased risk of death. We aimed to quantify changes in new diagnoses of AF following the onset of the COVID-19 pandemic. Investigating changes in new diagnoses of AF is of relevance because...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez, Inmaculada, He, Meiqi, Guo, Jingchuan, Tadrous, Mina, Gabriel, Nico, Swabe, Gretchen, Gellad, Walid F., Essien, Utibe R., Saba, Samir, Benjamin, Emelia J., Magnani, Jared W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894497/
https://www.ncbi.nlm.nih.gov/pubmed/36730318
http://dx.doi.org/10.1371/journal.pone.0281068
_version_ 1784881754410057728
author Hernandez, Inmaculada
He, Meiqi
Guo, Jingchuan
Tadrous, Mina
Gabriel, Nico
Swabe, Gretchen
Gellad, Walid F.
Essien, Utibe R.
Saba, Samir
Benjamin, Emelia J.
Magnani, Jared W.
author_facet Hernandez, Inmaculada
He, Meiqi
Guo, Jingchuan
Tadrous, Mina
Gabriel, Nico
Swabe, Gretchen
Gellad, Walid F.
Essien, Utibe R.
Saba, Samir
Benjamin, Emelia J.
Magnani, Jared W.
author_sort Hernandez, Inmaculada
collection PubMed
description BACKGROUND: Atrial fibrillation (AF) is associated with a five-fold increased risk of stroke and a two-fold increased risk of death. We aimed to quantify changes in new diagnoses of AF following the onset of the COVID-19 pandemic. Investigating changes in new diagnoses of AF is of relevance because delayed diagnosis interferes with timely treatment to prevent stroke, heart failure, and death. METHODS: Using De-identified Optum’s Clinformatics® Data Mart, we identified 19,500,401 beneficiaries continuously enrolled for 12 months in 2016-Q3 2020 with no history of AF. The primary outcome was new AF diagnoses per 30-day interval. Secondary outcomes included AF diagnosis in the inpatient setting, AF diagnosis in the outpatient setting, and ischemic stroke as initial manifestation of AF. We constructed seasonal autoregressive integrated moving average models to quantify changes in new AF diagnoses after the onset of the COVID-19 pandemic (3/11/2020, date of pandemic declaration). We tested whether changes in the new AF diagnoses differed by race and ethnicity. RESULTS: The average age of study participants was 51.0±18.5 years, and 52% of the sample was female. During the study period, 2.7% of the study sample had newly-diagnosed AF. New AF diagnoses decreased by 35% (95% CI, 21%-48%) after the onset of the COVID-19 pandemic, from 1.14 per 1000 individuals (95% CI, 1.05–1.24) to 0.74 per 1000 (95% CI, 0.64 to 0.83, p-value<0.001). New AF diagnoses decreased by 37% (95% CI, 13%- 55%) in the outpatient setting and by 29% (95% CI, 14%-43%) in the inpatient setting. The decrease in new AF diagnoses was similar across racial and ethnic subgroups. CONCLUSION: In a nationwide cohort of 19.5 million individuals, new diagnoses of AF decreased substantially following the onset of the COVID-19 pandemic. Our findings evidence pandemic disruptions in access to care for AF, which are concerning because delayed diagnosis interferes with timely treatment to prevent complications.
format Online
Article
Text
id pubmed-9894497
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-98944972023-02-03 COVID-19 pandemic and trends in new diagnosis of atrial fibrillation: A nationwide analysis of claims data Hernandez, Inmaculada He, Meiqi Guo, Jingchuan Tadrous, Mina Gabriel, Nico Swabe, Gretchen Gellad, Walid F. Essien, Utibe R. Saba, Samir Benjamin, Emelia J. Magnani, Jared W. PLoS One Research Article BACKGROUND: Atrial fibrillation (AF) is associated with a five-fold increased risk of stroke and a two-fold increased risk of death. We aimed to quantify changes in new diagnoses of AF following the onset of the COVID-19 pandemic. Investigating changes in new diagnoses of AF is of relevance because delayed diagnosis interferes with timely treatment to prevent stroke, heart failure, and death. METHODS: Using De-identified Optum’s Clinformatics® Data Mart, we identified 19,500,401 beneficiaries continuously enrolled for 12 months in 2016-Q3 2020 with no history of AF. The primary outcome was new AF diagnoses per 30-day interval. Secondary outcomes included AF diagnosis in the inpatient setting, AF diagnosis in the outpatient setting, and ischemic stroke as initial manifestation of AF. We constructed seasonal autoregressive integrated moving average models to quantify changes in new AF diagnoses after the onset of the COVID-19 pandemic (3/11/2020, date of pandemic declaration). We tested whether changes in the new AF diagnoses differed by race and ethnicity. RESULTS: The average age of study participants was 51.0±18.5 years, and 52% of the sample was female. During the study period, 2.7% of the study sample had newly-diagnosed AF. New AF diagnoses decreased by 35% (95% CI, 21%-48%) after the onset of the COVID-19 pandemic, from 1.14 per 1000 individuals (95% CI, 1.05–1.24) to 0.74 per 1000 (95% CI, 0.64 to 0.83, p-value<0.001). New AF diagnoses decreased by 37% (95% CI, 13%- 55%) in the outpatient setting and by 29% (95% CI, 14%-43%) in the inpatient setting. The decrease in new AF diagnoses was similar across racial and ethnic subgroups. CONCLUSION: In a nationwide cohort of 19.5 million individuals, new diagnoses of AF decreased substantially following the onset of the COVID-19 pandemic. Our findings evidence pandemic disruptions in access to care for AF, which are concerning because delayed diagnosis interferes with timely treatment to prevent complications. Public Library of Science 2023-02-02 /pmc/articles/PMC9894497/ /pubmed/36730318 http://dx.doi.org/10.1371/journal.pone.0281068 Text en © 2023 Hernandez et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Hernandez, Inmaculada
He, Meiqi
Guo, Jingchuan
Tadrous, Mina
Gabriel, Nico
Swabe, Gretchen
Gellad, Walid F.
Essien, Utibe R.
Saba, Samir
Benjamin, Emelia J.
Magnani, Jared W.
COVID-19 pandemic and trends in new diagnosis of atrial fibrillation: A nationwide analysis of claims data
title COVID-19 pandemic and trends in new diagnosis of atrial fibrillation: A nationwide analysis of claims data
title_full COVID-19 pandemic and trends in new diagnosis of atrial fibrillation: A nationwide analysis of claims data
title_fullStr COVID-19 pandemic and trends in new diagnosis of atrial fibrillation: A nationwide analysis of claims data
title_full_unstemmed COVID-19 pandemic and trends in new diagnosis of atrial fibrillation: A nationwide analysis of claims data
title_short COVID-19 pandemic and trends in new diagnosis of atrial fibrillation: A nationwide analysis of claims data
title_sort covid-19 pandemic and trends in new diagnosis of atrial fibrillation: a nationwide analysis of claims data
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894497/
https://www.ncbi.nlm.nih.gov/pubmed/36730318
http://dx.doi.org/10.1371/journal.pone.0281068
work_keys_str_mv AT hernandezinmaculada covid19pandemicandtrendsinnewdiagnosisofatrialfibrillationanationwideanalysisofclaimsdata
AT hemeiqi covid19pandemicandtrendsinnewdiagnosisofatrialfibrillationanationwideanalysisofclaimsdata
AT guojingchuan covid19pandemicandtrendsinnewdiagnosisofatrialfibrillationanationwideanalysisofclaimsdata
AT tadrousmina covid19pandemicandtrendsinnewdiagnosisofatrialfibrillationanationwideanalysisofclaimsdata
AT gabrielnico covid19pandemicandtrendsinnewdiagnosisofatrialfibrillationanationwideanalysisofclaimsdata
AT swabegretchen covid19pandemicandtrendsinnewdiagnosisofatrialfibrillationanationwideanalysisofclaimsdata
AT gelladwalidf covid19pandemicandtrendsinnewdiagnosisofatrialfibrillationanationwideanalysisofclaimsdata
AT essienutiber covid19pandemicandtrendsinnewdiagnosisofatrialfibrillationanationwideanalysisofclaimsdata
AT sabasamir covid19pandemicandtrendsinnewdiagnosisofatrialfibrillationanationwideanalysisofclaimsdata
AT benjaminemeliaj covid19pandemicandtrendsinnewdiagnosisofatrialfibrillationanationwideanalysisofclaimsdata
AT magnanijaredw covid19pandemicandtrendsinnewdiagnosisofatrialfibrillationanationwideanalysisofclaimsdata